METiS Pharmaceuticals Appoints Dr. Wei Xu as Chief Scientific Officer to Accelerate mRNA Pipeline Development

Mar 20, 2024 09:21 CST Updated 09:21

METiS TechBio

AI-Driven Drug Formulation Developer

METiS TechBio (METiS Pharmaceuticals), a company focused on "AI + Drug Delivery”METiS TechBio, an innovative biotechnology company, announced the appointment of Dr. Wei Xu as Chief Scientific Officer.Dr. Xu Wei will lead the drug discovery department, committed to building world-class drug discovery and translational medicine capabilities, advancing the mRNA pipeline to the clinical stage, and working with the management team to create a clinically differentiated drug pipeline.

Chief Scientific Officer of METiS TechBio, Dr. Wei Xu

Dr. Xu Wei is a scientist with a profound academic background in multiple fields such as immunology, oncology, and cell therapy.His academic career began at the Leiden University Medical Center in the Netherlands, where he earned his Ph.D. in 2007. He then joined the Baylor Institute for Immunology Research as a postdoctoral researcher, further accumulating valuable scientific research experience. While working at Roche Innovation Center (Switzerland), he led four pipelines into clinical stages, demonstrating excellent R&D management capabilities. From 2018 to 2022, Dr. Xu served as Vice President and Head of New Drug Biology and Translational Medicine at Innovent Biologics (Suzhou), where he helped the company establish teams in cell therapy and translational medicine, driving the company's R&D team to transition from "Me-too" drugs to FIC (First-in-Class) and BIC (Best-in-Class) drug capabilities. He subsequently joined Numab Therapeutics (Switzerland) as Chief Scientific Officer, responsible for formulating the company’s overall R&D and pipeline strategy.

Regarding joining METiS TechBio, Dr. Xu Wei said: "I am deeply honored to join METiS TechBio, a vibrant and innovative team. METiS has built the world’s first AI-driven drug delivery platform, leveraging precise targeting in drug delivery and drug discovery technologies, opening vast possibilities for the next generation of immunotherapy. I look forward to working with METiS's drug R&D team to build an innovative drug pipeline with global competitiveness.”

Academician Chen Hongmin

Co-founder of METiS TechBio&President of the U.S. Company, Head of R&D

Dr. Xu Wei is a world-class expert in drug research and development. His extensive experience and outstanding capabilities will bring new momentum and vitality to our R&D efforts. We believe that under his leadership, our drug discovery department will achieve greater breakthroughs, accelerate the development of the mRNA pipeline, and develop more effective therapeutic drugs for patients worldwide.

Dr. Lai Cai Da

Co-founder & CEO of METiS TechBio

The joining of Dr. Xu WeiAgentMETiS TechBio has injected strong research and development capabilities. As an innovative biotechnology company committed to advancing the development of AI-driven drug and delivery system platforms, we have made significant progress in the small molecule drug field through independent research and development, advancing multiple pipelines to the clinical stage, with the fastest reaching Phase III clinical trials. Next, nucleic acid drugs will be another strategic focus. We look forward to METiS TechBio achieving even greater success in drug research and development under the leadership of Dr. Xu Wei.

About METiS TechBio

METiS TechBio is an innovative biotechnology company that uses artificial intelligence (AI)-driven, precision-targeted drug delivery and drug discovery technologies to develop more effective therapeutic drugs for patients. With its leading "AI + drug delivery" technology, METiS TechBio focuses on advancing the research and development of novel or best-in-class drugs, as well as improving existing therapies. It aims to develop more effective treatments for patients worldwide more efficiently and precisely, filling the gap in the "undruggable" market.

Led by Academician Chen Hongmin, Dr. Lai Caida, and Dr. Wang Wenshou, top scientists from MIT, METiS TechBio has become one of the world's leading RNA drug delivery platforms. METiS TechBio has independently developed three major AI+ core technology platforms: AiTEM (AI-driven small molecule formulation design platform), AiLNP (AI-driven nucleic acid delivery system design platform), and AiRNA (AI-driven mRNA sequence design platform). Through these three technology platforms, the company has successfully built more than 10 drug pipelines, covering small molecule drugs and nucleic acid drugs based on mRNA. The focus is on indications with significant clinical needs in China and globally, such as cancer, central nervous system disorders, and liver diseases.

Currently, the company has developed more than ten R&D pipelines, including small molecule drugs and nucleic acid drugs based on mRNA, with the speed and success rate of R&D being recognized by world-leading pharmaceutical enterprises. As a new generation biotechnology company, METiS TechBio will continue to lead industry innovation and make greater contributions to global healthcare.

Learn More About METiS TechBio

END

2023 Year-End Review | AI-Driven Innovation, Delivery Leading Change

The Innovation Rivalry of mRNA Delivery Under the Nobel Prize | Jianghu

Success is often not replicable; what's important is to find your own path.